LENTIPEAK Trademark

Trademark Overview

On Wednesday, November 2, 2022, a trademark application was filed for LENTIPEAK with the United States Patent and Trademark Office. The USPTO has given the LENTIPEAK trademark a serial number of 97659358. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Friday, October 31, 2025. This trademark is owned by elevatebio, LLC. The LENTIPEAK trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Custom manufacture of cell and gene therapies and regenerative medicines
lentipeak

General Information

Serial Number97659358
Word MarkLENTIPEAK
Filing DateWednesday, November 2, 2022
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateFriday, October 31, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 3, 2023

Trademark Statements

Goods and ServicesCustom manufacture of cell and gene therapies and regenerative medicines

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateSunday, November 20, 2022
Primary Code040
First Use Anywhere DateThursday, November 3, 2022
First Use In Commerce DateThursday, November 3, 2022

Trademark Owner History

Party Nameelevatebio, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142
Party Nameelevatebio, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Saturday, November 5, 2022NEW APPLICATION ENTERED
Sunday, November 20, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 16, 2023ASSIGNED TO EXAMINER
Monday, August 28, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, August 28, 2023EXAMINERS AMENDMENT E-MAILED
Monday, August 28, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, August 28, 2023EXAMINER'S AMENDMENT ENTERED
Monday, August 28, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 13, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 3, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 28, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 23, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 23, 2024SOU EXTENSION 1 FILED
Thursday, May 23, 2024SOU EXTENSION 1 GRANTED
Friday, May 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 15, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 15, 2024SOU EXTENSION 2 FILED
Friday, November 15, 2024SOU EXTENSION 2 GRANTED
Friday, November 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 22, 2025TEAS STATEMENT OF USE RECEIVED
Friday, October 31, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 22, 2025USE AMENDMENT FILED
Friday, October 31, 2025STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

lentipeak regenerative medicines therapies gene manufacture cell custom